SII gets purchase order from Govt for 10 crore Covishield doses
New Delhi: The Centre has placed a new purchase order with the Serum Institute of India (SII) for the supply of 10 crore doses of the Oxford-AstraZeneca COVID-19 vaccine, Covishield, each costing Rs 157.50, including GST, according to official sources.
The HLL Lifecare Limited, a public sector undertaking, has issued the supply order on behalf of the Union health ministry on March 12 in the name of Prakash Kumar Singh, Director, Government and Regulatory Affairs at the Pune-based SII.
The cost of the 10 crore doses would be borne by the health ministry under the budgetary allocation for the purpose.
The expenditure for the earlier orders of the vaccines was funded through the PM Cares Fund, the sources said.
India has approved two vaccines against COVID-19 -- Covishield, manufactured by the SII, and the indigenously-developed Covaxin of Bharat Biotech -- for restricted emergency use in the country.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.